AstraZeneca’s Alexion Signs $825M AAV Capsid Deal with JCR Pharma

Alexion, part of AstraZeneca Rare Disease, has entered a license agreement with JCR Pharmaceuticals for its proprietary JUST-AAV capsid platform to advance gene therapies for rare diseases1 2 3 4 5.

The JUST-AAV platform consists of modified adeno-associated virus (AAV) vectors engineered for highly targeted delivery to specific tissues, including the brain, muscle, and liver1 3 5.

Alexion will be able to use the licensed capsid technology in up to five genomic medicine programs1 3 4 5.

JCR receives an upfront payment and could earn up to $825 million in development and sales milestone payments if all five targets are exercised, plus tiered royalties on net sales1 3 4 5.

This is the third collaboration between JCR and Alexion, expanding on earlier partnerships focused on J-Brain Cargo technology1 3.

The agreement is expected to have a financial impact included in JCR’s fiscal year ending March 31, 20261.

Sources:

1. https://www.packgene.com/frontier/070725-jcr-pharmaceuticals/

2. https://www.biospectrumasia.com/news/50/26324/japans-jcr-pharma-licenses-gene-therapy-platform-to-astrazeneca-rare-disease-unit-for-825-m.html

3. https://www.worldpharmaceuticals.net/news/jcr-alexion-collaborate-on-genomic-medicines/

4. https://firstwordpharma.com/story/5979394

5. https://trial.medpath.com/news/3e4fbf2a29b47f2a/jcr-pharmaceuticals-licenses-just-aav-gene-therapy-platform-to-alexion-in-825-million-deal

Sources:

Leave a Reply Cancel reply